High LDL cholesterol is silent. It damages arteries progressively and leads to heart attacks and strokes, and it produces no symptoms along the way, so nothing reminds a patient that the therapy matters.
PCSK9-lowering therapies come with different injection schedules — self-injected monoclonal antibodies on one rhythm, clinician-administered inclisiran twice a year. Patients lose track.
Hospitals and cardiologists rarely have a structural process or the staff to onboard patients and check whether injections happen on time. The result is inconsistent use of therapies that are both expensive and life-saving, and for the sponsor an adherence gap that reduces real-world impact and weakens the evidence base.
Automated SMS reminders ahead of each injection. No app to install, no account to create, no smartphone requirement — which matters in a population that skews older.
Hospitals get a simple onboarding flow and a dashboard showing who is on schedule and who needs attention. The program adapts to both the self-injected schedules and the twice-yearly inclisiran rhythm, and deploys across countries with minimal setup.
Many first- and second-degree relatives of an FH patient remain undiagnosed while carrying the same risk. The program includes a patient-driven family-tree module that guides an FH patient through mapping their relatives and inviting them for screening — structured cascade testing without additional workload for the care team.
Tell us what you are working on and we will help you get it moving.
